Australian Government

Department of Health and Ageing

SCHEDULE OF PHARMACEUTICAL BENEFITS

SUMMARY OF CHANGES

EFFECTIVE 1 JUNE 2008

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 June 2008. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 June 2008 and are included, where applicable, in prices published in the Schedule—

Dispensing Fees:	Ready-prepared	$5.44
	Dangerous drug fee	$2.71
	Extemporaneously-prepared	$7.48
	Allowable additional patient charge*	$3.63
Additional Fees (for safety net prices):	Ready-prepared	$1.01
	Extemporaneously-prepared	$1.40
Patient Co-payments:	General	$31.30
	Concessional	$5.00
Safety Net Thresholds:	General	$1141.80
	Concessional	$290.00
Safety Net Card Issue Fee:		$7.86

*The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

SUMMARY OF CHANGES

ADDITIONS

Additions — Items

(see under 'RESTRICTIONS' below for full details)

9155W **Duloxetine hydrochloride**, Capsule 30 mg (base) (*Cymbalta*)
9156X **Duloxetine hydrochloride**, Capsule 60 mg (base) (*Cymbalta*)
9154T **Glucose indicator—blood**, Electrode strips, 100 (*FreeStyle Lite*)
9151P **Pramipexole hydrochloride**, Tablet 125 micrograms (*Sifrol*)
9152Q **Pramipexole hydrochloride**, Tablet 250 micrograms (*Sifrol*)
9153R **Pramipexole hydrochloride**, Tablet 1 mg (*Sifrol*)

Additions — Brands

8220P *Celica, RA* — **Citalopram hydrobromide**, Tablet 20 mg (base)
8561N *Meloxicam Winthrop, WA* — **Meloxicam**, Tablet 7.5 mg
8562P *Meloxicam Winthrop, WA* — **Meloxicam**, Tablet 15 mg
1970Q *Quinapril Sandoz, SZ* — **Quinapril hydrochloride**, Tablet 20 mg (base)

Deletions — Items

1528K **Flucloxacillin**, Powder for syrup 125 mg (as magnesium) per 5 mL, 100 mL (*Floxapen*)
5092B **Flucloxacillin**, Powder for syrup 125 mg (as magnesium) per 5 mL, 100 mL (*Floxapen*) **(Dental)**

Deletions — Brands

8220P *Citalopram-RL, RE* — **Citalopram hydrobromide**, Tablet 20 mg (base)
1215Y *Dymadon Forte, GK* — **Codeine phosphate with paracetamol**, Tablet 30 mg-500 mg
8785J *Dymadon Forte, GK* — **Codeine phosphate with paracetamol**, Tablet 30 mg-500 mg **(Diff. Max. Qty)**
3316M *Dymadon Forte, GK* — **Codeine phosphate with paracetamol**, Tablet 30 mg-500 mg **(Dental)**
8559L *Pharmacor Gabapentin 600, CR* — **Gabapentin**, Tablet 600 mg
8389M *Pharmacor Gabapentin 800, CR* — **Gabapentin**, Tablet 800 mg
1486F *Amizide, AF* — **Hydrochlorothiazide with amiloride hydrochloride**, Tablet 50 mg-5 mg
8539K *Oxaliplan 50, WQ* — **Oxaliplatin**, Powder for I.V. infusion 50 mg
8540L *Oxaliplan 100, WQ* — **Oxaliplatin**, Powder for I.V. infusion 100 mg
2833D *Pravastatin-RL, RE* — **Pravastatin sodium**, Tablet 10 mg
2834E *Pravastatin-RL, RE* — **Pravastatin sodium**, Tablet 20 mg
8197K *Pravastatin-RL, RE* — **Pravastatin sodium**, Tablet 40 mg
1760P *Roxithromycin-RL, RE* — **Roxithromycin**, Tablet 150 mg
8016X *Roxithromycin-RL, RE* — **Roxithromycin**, Tablet 300 mg
2013Y *Simvastatin-RL, RE* — **Simvastatin**, Tablet 5 mg
2011W *Simvastatin-RL, RE* — **Simvastatin**, Tablet 10 mg
2012X *Simvastatin-RL, RE* — **Simvastatin**, Tablet 20 mg
8173E *Simvastatin-RL, RE* — **Simvastatin**, Tablet 40 mg
8313M *Simvastatin-RL, RE* — **Simvastatin**, Tablet 80 mg

Deletions - Bioequivalence Indicator

The bioequivalence indicator ([a]) has been removed from the following **brand**:

1486F *Moduretic , MK* — **Hydrochlorothiazide with amiloride hydrochloride**, Tablet 50 mg-5 mg

ALTERATIONS

Alterations — Restrictions

(see under 'RESTRICTIONS' below for full details)

8646C **Tacrolimus**, Capsule 500 micrograms (*Prograf*)

8647D **Tacrolimus**, Capsule 1 mg (*Prograf*)

8648E **Tacrolimus**, Capsule 5 mg (*Prograf*)

Alterations — Manufacturer's Code

		From	*To*
2019G	**Acitretin**, Capsule 10 mg (*Neotigason*)	RO	TA
2020H	**Acitretin**, Capsule 25 mg (*Neotigason*)	RO	TA
8560M	**Calcium**, Tablet 250 mg (as citrate) (*Citracal*)	KY	BN
8318T	**Clarithromycin**, Tablet 250 mg (*Clarihexal*)	HX	SZ
8284B	**Raltitrexed**, Powder for I.V. infusion 2 mg (*Tomudex*)	AP	HH

SECTION 100 — HIGHLY SPECIALISED DRUGS PROGRAM

ADDITIONS

Additions — Brand

9607P *Apomine, HH* — **Apomorphine hydrochloride**, Injection 20 mg in 2 mL

DELETIONS

Deletions — Item

6104G **Apomorphine hydrochloride**, Injection 10 mg in 1 mL (*Apomine*)

ALTERATIONS

Alterations — Restrictions

(see under 'RESTRICTIONS' below for full details)

6328C **Tacrolimus**, Capsule 500 micrograms (*Prograf*)

6216E **Tacrolimus**, Capsule 1 mg (*Prograf*)

6217F **Tacrolimus**, Capsule 5 mg (*Prograf*)

Alterations — Manufacturer's Code

		From	*To*
9607P	**Apomorphine hydrochloride**, Injection 20 mg in 2 mL (*APO-go*)	HH	FA

ADVANCE NOTICES

Advance Notices - Deletion of Items

The following item will be deleted from the Schedule of Pharmaceutical Benefits on 1 **July** 2008:
Deletion requested by manufacturer -

2695W **Hydroxocobalamin acetate**, Injection 1 mg (base) in 1 mL (*Goldshield Hydroxocobalamin*)

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 **August** 2008:
Items discontinued by the manufacturer —

9002T **Benzathine penicillin**, Powder for injection 900 mg (1,200,000 i.u.) (*Pan Benzathine Benzylpenicillin*)

5252K **Benzathine penicillin**, Powder for injection 900 mg (1,200,000 i.u.) (*Pan Benzathine Benzylpenicillin*) **(Dental)**

9003W **Benzathine penicillin**, Powder for injection 900 mg (1,200,000 i.u.) (*Pan Benzathine Benzylpenicillin*)

RESTRICTIONS

The text of restrictions mentioned above:

9155W **Duloxetine hydrochloride**, Capsule 30 mg (base) (*Cymbalta*)

9156X **Duloxetine hydrochloride**, Capsule 60 mg (base) (*Cymbalta*)

Restricted benefit

Major depressive disorders

9151P **Pramipexole hydrochloride**, Tablet 125 micrograms (*Sifrol*)
9153R **Pramipexole hydrochloride**, Tablet 1 mg (*Sifrol*)
9152Q **Pramipexole hydrochloride**, Tablet 250 micrograms (*Sifrol*)

CAUTION:

Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug

Restricted benefit

Parkinson's disease as adjunctive therapy in patients being treated with levodopa—decarboxylase inhibitor combinations

Tacrolimus

CAUTION:

Careful monitoring of patients is mandatory

8647D **Tacrolimus**, Capsule 1 mg (*Prograf*)
8646C **Tacrolimus**, Capsule 500 micrograms (*Prograf*)
8648E **Tacrolimus**, Capsule 5 mg (*Prograf*)

Authority required

Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with liver transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application

Authority required

Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with renal transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application

Authority required

Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with cardiac transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application

Authority required

Maintenance therapy, following initiation and stabilisation of treatment with tacrolimus and where therapy remains under the supervision and direction of the transplant unit reviewing that patient, of patients with lung transplants. The name of the specialised transplant unit reviewing treatment and the date of the latest review at the specialised transplant unit must be included in the authority application

6216E **Tacrolimus**, Capsule 1 mg (*Prograf*)
6328C **Tacrolimus**, Capsule 500 micrograms (*Prograf*)

6217F **Tacrolimus**, Capsule 5 mg (*Prograf*)

Private hospital authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis and treatment of liver allograft rejection. Management includes initiation, stabilisation and review of therapy as required

Private hospital authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis and treatment of renal allograft rejection. Management includes initiation, stabilisation and review of therapy as required

Private hospital authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis and treatment of cardiac allograft rejection. Management includes initiation, stabilisation and review of therapy as required

Private hospital authority required

Management of rejection, under the supervision and direction of a transplant unit, in patients receiving this drug for prophylaxis and treatment of lung allograft rejection. Management includes initiation, stabilisation and review of therapy as required

REPATRIATION PHARMACEUTICAL BENEFITS

This Schedule is effective from 1 June 2008 and all previous issues are cancelled.

New Schedules take effect on the first day of each month.

SUMMARY OF CHANGES

ALTERATIONS

Alterations — Maximum Quantity

		From	*To*
4914P	**Dressing—hydrogel—amorphous**, Tube 50 g (*Solugel 10336*)	12	3

Alterations - Number of Repeats

		From	*To*
4914P	**Dressing—hydrogel—amorphous**, Tube 50 g (*Solugel 10336*)	1	3

Alterations — Manufacturer's Code

		From	*To*
4332B	**Calcium**, Tablet 250 mg (as citrate) (*Citracal*)	KY	BN
4093K	**Calcium**, Tablet 250 mg (as citrate) (*Citracal*) **(Diff. Max. Qty)**	KY	BN